The aim of this review is to determine the clinical effectiveness and safety of intravenous immunoglobulin for JIA.

This review will address two core questions:

1. What is the clinical efficacy of intravenous immunoglobulin for the treatment of JIA in terms of controlling the disease and reducing joint counts?

2. What are the risks (frequency and severity of adverse events) associated with immunoglobulin treatment in these patients?